DAXX safeguards heterochromatin formation in embryonic stem cells.

Chromocenters DAXX Embryonic stem cell Heterochromatin Histone variant H3.3 Nuclear periphery PML Pericentromere SETDB1

Journal

Journal of cell science
ISSN: 1477-9137
Titre abrégé: J Cell Sci
Pays: England
ID NLM: 0052457

Informations de publication

Date de publication:
01 Oct 2023
Historique:
received: 24 02 2023
accepted: 25 08 2023
pubmed: 1 9 2023
medline: 1 9 2023
entrez: 1 9 2023
Statut: ppublish

Résumé

Genomes comprise a large fraction of repetitive sequences folded into constitutive heterochromatin, which protect genome integrity and cell identity. De novo formation of heterochromatin during preimplantation development is an essential step for preserving the ground-state of pluripotency and the self-renewal capacity of embryonic stem cells (ESCs). However, the molecular mechanisms responsible for the remodeling of constitutive heterochromatin are largely unknown. Here, we identify that DAXX, an H3.3 chaperone essential for the maintenance of mouse ESCs in the ground state, accumulates in pericentromeric regions independently of DNA methylation. DAXX recruits PML and SETDB1 to promote the formation of heterochromatin, forming foci that are hallmarks of ground-state ESCs. In the absence of DAXX or PML, the three-dimensional (3D) architecture and physical properties of pericentric and peripheral heterochromatin are disrupted, resulting in de-repression of major satellite DNA, transposable elements and genes associated with the nuclear lamina. Using epigenome editing tools, we observe that H3.3, and specifically H3.3K9 modification, directly contribute to maintaining pericentromeric chromatin conformation. Altogether, our data reveal that DAXX is crucial for the maintenance and 3D organization of the heterochromatin compartment and protects ESC viability.

Identifiants

pubmed: 37655670
pii: 326618
doi: 10.1242/jcs.261092
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Agence Nationale pour le Developpement de la Recherche Universitaire
ID : ANR-16-CE12-0003-01
Organisme : Ligue Contre le Cancer
ID : RS22/75-43
Organisme : Agence Nationale de la Recherche
ID : ANR-16-CE12-0003-01
Organisme : La Ligue Nationale Contre le Cancer
ID : RS22/75-43
Organisme : IDEX SLI
ID : DXCAIHUSLI-EF14

Informations de copyright

© 2023. Published by The Company of Biologists Ltd.

Déclaration de conflit d'intérêts

Competing interests The authors declare no competing or financial interests.

Auteurs

Antoine Canat (A)

Université de Paris, Laboratoire Génomes, Biologie Cellulaire et Thérapeutiques, CNRS UMR7212, INSERM U944, Institut de Recherche St Louis, F-75010 Paris, France.

Adeline Veillet (A)

Université de Paris, Laboratoire Génomes, Biologie Cellulaire et Thérapeutiques, CNRS UMR7212, INSERM U944, Institut de Recherche St Louis, F-75010 Paris, France.

Renaud Batrin (R)

Université de Paris, Laboratoire Génomes, Biologie Cellulaire et Thérapeutiques, CNRS UMR7212, INSERM U944, Institut de Recherche St Louis, F-75010 Paris, France.

Clara Dubourg (C)

Université de Paris, Laboratoire Génomes, Biologie Cellulaire et Thérapeutiques, CNRS UMR7212, INSERM U944, Institut de Recherche St Louis, F-75010 Paris, France.

Priscillia Lhoumaud (P)

Université Paris Cité, CNRS, Institut Jacques Monod, F-75013 Paris, France.

Pol Arnau-Romero (P)

Université Paris Cité, CNRS, Institut Jacques Monod, F-75013 Paris, France.

Maxim V C Greenberg (MVC)

Université Paris Cité, CNRS, Institut Jacques Monod, F-75013 Paris, France.

Frédéric Bonhomme (F)

Institut Pasteur, Université Paris Cité, CNRS, Epigenetic Chemical Biology, UMR 3523, F-75724 Paris, France.

Paola B Arimondo (PB)

Institut Pasteur, Université Paris Cité, CNRS, Epigenetic Chemical Biology, UMR 3523, F-75724 Paris, France.

Robert Illingworth (R)

Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh BioQuarter, 5 Little France Drive, Edinburgh EH16 4UU, UK.

Emmanuelle Fabre (E)

Université de Paris, Laboratoire Génomes, Biologie Cellulaire et Thérapeutiques, CNRS UMR7212, INSERM U944, Institut de Recherche St Louis, F-75010 Paris, France.

Pierre Therizols (P)

Université de Paris, Laboratoire Génomes, Biologie Cellulaire et Thérapeutiques, CNRS UMR7212, INSERM U944, Institut de Recherche St Louis, F-75010 Paris, France.

Classifications MeSH